With up to 57% of AML patients having refractory AML or experienced a relapse or death within 12 months of diagnosis [51], what is important is the fact that both ALDH1A1 and ALDH2 enzymes can be targeted by molecules that inhibit both activities. The gene discussed is ALDH1A1; the disease is acute myeloid leukemia.